Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tonkin

Showing results (111-120 of 163) with videos related to

Pageof 17
Sort By:
Frontiers in Medicine|September 12, 2022
Effect of atorvastatin on skeletal muscles of patients with knee osteoarthritis: <i>Post-hoc</i> analysis of a randomised controlled trialYuan Z Lim, Flavia M Cicuttini, Anita E Wluka, et al.
BMC Neurology|February 10, 2012
Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion)Christopher M Reid, Elsdon Storey, Tien Y Wong, et al.
Cardiovascular Therapeutics|August 18, 2015
The Effect of a Cardiovascular Polypill Strategy on Pill BurdenMichael Truelove, Anushka Patel, Severine Bompoint, et al.
Circulation|March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes, Ian C Marschner, David Hunt, et al.
Journal of the American College of Cardiology|October 22, 2013
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease)Harvey D White, Andrew Tonkin, John Simes, et al.
Circulation|September 15, 2004
Effect of pravastatin on cardiovascular events in people with chronic kidney diseaseMarcello Tonelli, Chris Isles, Gary C Curhan, et al.
Journal of the American College of Cardiology|May 6, 2014
Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium?Harvey D White, Andrew Tonkin, John Simes, et al.
International Journal of Cardiology|July 22, 2017
Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction modelAndrea Driscoll, Elizabeth H Barnes, Stefan Blankenberg, et al.
Circulation|November 4, 2024
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-AnalysisHarpreet S Bhatia, Simon Wandel, Peter Willeit, et al.
International Journal of Cardiology|May 6, 2021
Risk stratification of cardiovascular complications using CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> scores in chronic atherosclerotic cardiovascular diseaseJonathan Sen, Andrew Tonkin, John Varigos, et al.
Pageof 17

Showing results (111-120 of 163) with videos related to

Sort By:
Pageof 17
Frontiers in Medicine|September 12, 2022
Effect of atorvastatin on skeletal muscles of patients with knee osteoarthritis: <i>Post-hoc</i> analysis of a randomised controlled trialYuan Z Lim, Flavia M Cicuttini, Anita E Wluka, et al.
BMC Neurology|February 10, 2012
Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion)Christopher M Reid, Elsdon Storey, Tien Y Wong, et al.
Cardiovascular Therapeutics|August 18, 2015
The Effect of a Cardiovascular Polypill Strategy on Pill BurdenMichael Truelove, Anushka Patel, Severine Bompoint, et al.
Circulation|March 13, 2002
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes, Ian C Marschner, David Hunt, et al.
Journal of the American College of Cardiology|October 22, 2013
Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease)Harvey D White, Andrew Tonkin, John Simes, et al.
Circulation|September 15, 2004
Effect of pravastatin on cardiovascular events in people with chronic kidney diseaseMarcello Tonelli, Chris Isles, Gary C Curhan, et al.
Journal of the American College of Cardiology|May 6, 2014
Reply: the latest generation of troponin immunoassays: the "cholesterol" of the third millennium?Harvey D White, Andrew Tonkin, John Simes, et al.
International Journal of Cardiology|July 22, 2017
Predictors of incident heart failure in patients after an acute coronary syndrome: The LIPID heart failure risk-prediction modelAndrea Driscoll, Elizabeth H Barnes, Stefan Blankenberg, et al.
Circulation|November 4, 2024
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-AnalysisHarpreet S Bhatia, Simon Wandel, Peter Willeit, et al.
International Journal of Cardiology|May 6, 2021
Risk stratification of cardiovascular complications using CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> scores in chronic atherosclerotic cardiovascular diseaseJonathan Sen, Andrew Tonkin, John Varigos, et al.
Pageof 17